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Abstract HIV-1-infected patients with suppressed
plasma viral loads often require changes to their
antiretroviral (ARV) therapy to manage drug toxicity and
intolerance, to improve adherence, and to avoid drug
interactions. In patients who have never experienced
virologic failure while receiving ARV therapy and who
have no evidence of drug resistance, switching to any of
the acceptable US Department of Health and Human Ser-
vices first-line therapies is expected to maintain virologic
suppression. However, in virologically suppressed patients
with a history of virologic failure or drug resistance, it can
be more challenging to change therapy while still main-
taining virologic suppression. In these patients, it may be
difficult to know whether the discontinuation of one of the
ARVs in a suppressive regimen constitutes the removal of
a key regimen component that will not be adequately
supplanted by one or more substituted ARVs. In this arti-
cle, we review many of the clinical scenarios requiring
ARV therapy modification in patients with stable virologic
suppression and outline the strategies for modifying ther-
apy while maintaining long-term virologic suppression.
Key Points
In patients who have never experienced virologic
failure while receiving ART and have no evidence of
drug resistance, switching from stable suppressive
therapy to any of the acceptable DHHS first-line
regimens is expected to maintain virologic
suppression.
ART modifications in patients with known drug
resistance or prior virologic failure requires
knowledge of past regimens, past episodes of failure,
and past genotypic resistance tests when switching
and it is usually necessary to select a regimen with a
high genetic barrier to resistance.
Several reduced intensity regimens may provide
treatment modification options for carefully selected
patients with medication intolerance or co-
morbidities, but typically carry an increased risk of
virologic failure and require excellent medication
adherence and close follow-up.
1 Introduction
Advances in antiretroviral (ARV) therapy (ART) have
made it possible to achieve and maintain virologic sup-
pression in nearly all HIV-1-infected patients. However,
even patients with sustained virologic suppression require
ART changes to manage acute toxicities, limit long-term
adverse effects, improve adherence, and avoid drug–drug
interactions [1, 2]. Indeed, ART is modified more com-
monly for these indications than for virologic failure (VF)
[3–6]. ART modification in patients with stable virologic
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suppression has been reported in more than one-third of
patients on first-line ART over a 7-year period in a large
Canadian cohort and between 8 and 43 % annually in a
variety of other clinical cohorts [3–5, 7–10].
Although modifying a suppressive ART regimen may be
beneficial or even required for many patients, it carries a
risk of VF and the development of resistance to one or
more of the ARVs in a patient’s modified regimen [9]. This
risk is heightened in patients with a history of VF because
potentially not all ARVs in such patients’ regimens will be
fully active. Therefore, modifying or switching therapy in
such patients requires a review of past and current ARV
regimens.
As new ARVs with improved toxicity profiles have been
developed, there have been an increasing number of clin-
ical trials of ART modification in virologically suppressed
patients, and many of these studies have been summarized
in an excellent review by Van den Eynde and Podzamczer
[11]. Together, these trials provide guidance for several
specific clinical scenarios and outline important principles
necessary to maintain virologic suppression while changing
therapy. However, many clinical scenarios and ART
modification strategies have not been evaluated in ran-
domized clinical trials and are instead supported primarily
by non-randomized trials, observational cohort studies, and
expert opinion. Here we review many of the clinical sce-
narios requiring ART modification in patients with
stable virologic suppression and the accompanying strate-
gies for modifying therapy while maintaining long-term
virologic suppression.
2 Indications for Antiretroviral Therapy (ART)
Modification
In the earliest years of ART, several studies attempted to
limit the potential toxicity of ART by reducing the number
of ARVs prescribed to virologically suppressed patients
[12–14]. The VF rates in these early studies were unac-
ceptably high, in part because virologic suppression was
defined by insensitive virus load assays with lower limits of
detection of 400–500 copies/ml and in part because the
ARVs used to attain virologic suppression were less effi-
cacious than the ARVs used now. As a result of these early
failures and the improved tolerability of current ARVs, the
strategy of simply removing an ARV from the regimen of a
patient with stable virologic suppression is now studied
primarily in patients receiving medications with a high
genetic barrier to resistance, most commonly pharmaco-
logically boosted protease inhibitors (PIs).
There have also been several intensification studies in
which an ARV is added to the regimen of a patient with
stable virologic suppression. The goal of these studies was
to eliminate or reduce the residual levels of viremia that
can often be detected with highly sensitive single-copy
HIV-1 assays [15]. The rationale for these studies was
based on the hypothesis that even very low levels of virus
(fewer than 50 copies/ml) may be associated with damag-
ing systemic inflammation and replenishment of the HIV-1
proviral DNA reservoir. Intensification studies, however,
generally demonstrated no clinical benefit or effect on low-
level residual viremia using highly sensitive single-copy/
ml assays [15–18]. As a result, the addition of an ARV to
the regimen of a patient with stably suppressed viremia is
not recommended.
Table 1 is a comprehensive list of the main indications
for switching ARVs in patients with stable virologic sup-
pression. Among the most common chronic toxicities and
forms of intolerance leading to ARV switches are gas-
trointestinal intolerance, lipid or other metabolic abnor-
malities, coronary artery disease, neuropsychiatric
symptoms, renal dysfunction, and jaundice caused by
unconjugated hyperbilirubinemia. Mitochondrial toxicity
and injection site reactions are currently uncommon causes
of treatment switches because there has been a marked
decrease in the use of the mitochondrial toxic nucleoside
reverse transcriptase inhibitors (NRTIs)—stavudine (d4T),
didanosine (ddI), and zidovudine (AZT)—and of the par-
enteral fusion inhibitor enfuvirtide (ENF).
Co-morbid conditions typically necessitate ARV regi-
men changes when they exacerbate a pre-existing ARV-
associated toxicity or require the use of a medication that
has undesired or unpredictable pharmacologic interactions
with an ARV in a patient’s regimen. For example,
switching ARVs to avoid interaction with rifamycins dur-
ing tuberculosis (TB) therapy is common in areas in which
TB is endemic. Switching ARVs to limit pharmacologic
interactions with direct-acting antivirals for hepatitis C
treatment or to improve absorption in patients receiving
proton-pump inhibitors is common in upper-income
regions (Table 1).
There are also numerous drug–drug interactions
between ARVs and other commonly prescribed drugs.
Although the effects of many of these interactions on drug
absorption and metabolism have been well characterized,
other empirically observed interactions are poorly under-
stood. As a result, there is no substitute for reviewing the
potential interactions of a new ARV with each medication
a patient is receiving. The US Department of Health and
Human Services (DHHS) guidelines document contains an
extensive highly accessible series of tables containing the
most common interactions associated with each ARV.
There are also several up-to-date authoritative websites
containing even more extensive information on drug–drug
interactions such as the one maintained by the University
of Liverpool: http://www.hiv-druginteractions.org.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































78 S. E. Collins et al.
Pre-conception counseling coupled with prospective
ART modification for women likely to become pregnant
will reduce the likelihood that ART will need to be chan-
ged during pregnancy. The DHHS preferred regimens for
treatment-naı¨ve pregnant patients include ritonavir-boosted
atazanavir (ATV/r), darunavir (DRV/r), or raltegravir
(RAL) in combination with one of the following NRTI
backbones: abacavir (ABC)/lamivudine (3TC), tenofovir
disoproxil fumarate (TDF)/emtricitabine (FTC), TDF/3TC,
or AZT/3TC [44]. The initiation of efavirenz (EFV) is not
recommended during the first 8 weeks after conception in
treatment-naı¨ve patients. However, as pregnancy is fre-
quently not detected until several weeks after conception,
this recommendation is relevant primarily for the choice of
therapy in women planning to conceive.
Pharmacokinetic changes may lower PI plasma levels
during the third trimester of pregnancy [44]. Therefore
ritonavir-boosted lopinavir (LPV/r) and DRV/r should be
administered twice daily and unboosted ATV is not rec-
ommended. Although there are fewer data on the safety to
the fetus of both the most recently approved ARVs such as
elvitegravir (EVG), dolutegravir (DTG), cobicistat, and
tenofovir alafenamide (TAF) and the more rarely used
ARVs such as tipranavir (TPV), maraviroc (MVC), and
ENF, no ARVs, other than the combined use of d4T and
ddI, are specifically contraindicated [44]. ARV switches
during pregnancy may also be associated with a greater risk
of VF compared with continued unchanged therapy, sup-
porting the recommendation that pregnant patients be
managed in consultation with specialists experienced in
treating HIV in pregnancy [48].
Adherence to ART is essential for both attaining and
sustaining virologic suppression. Adherence can be influ-
enced by several factors under the control of a health-care
provider including the selection of a well tolerated ART
regimen with an uncomplicated dosing schedule. Fixed-
dose combinations (FDCs) improve adherence and reduce
the risk of drug resistance by preventing patients from
accidentally or intentionally not taking all of their pre-
scribed drugs. Five single-tablet FDCs suitable for both
first-line therapy and, many maintenance therapy scenarios,
have been approved by the US Food and Drug Adminis-
tration (FDA).
Patients who are responsible for a significant proportion
of the cost of an ART regimen either through cost-sharing
or individual drug co-payments are at higher risk of non-
adherence. It is not possible to provide specific recom-
mendations on which regimens are associated with the
lowest cost to a patient because these are typically driven
by market forces and negotiations among pharmaceutical
companies, treatment programs, and third-party payers.
Nonetheless, health-care providers should be aware of the

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Modifying Antiretroviral Therapy 79
3 Clinical Trials of ART Modification
ART modification trials can be divided into those enrolling
patients with no history of VF who are receiving an initial
or early ART regimen and those enrolling patients who
may have a history of VF with documented or suspected
drug resistance. In patients with stable virologic suppres-
sion and no history of VF, many ART regimens are likely
to be effective options when a change in therapy is nec-
essary. Indeed, each of the regimens classified by the
DHHS into Recommended, Alternative, or Other options
for first-line therapy (Table 2) appear to be acceptable op-
tions for patients with stable virologic suppression and no
history of VF. For example, TDF/FTC/rilpivirine (RPV) is
categorized as an Alternative option for first-line therapy
because it is not recommended for patients with plasma
HIV-1 RNA levels above 5.0 log copies/ml. However, it
has been shown to be highly effective in patients with
stable virologic suppression regardless of their pre-therapy
plasma HIV-1 RNA level [49].
It is more challenging to modify therapy in virologically
suppressed patients with a history of VF. In such patients it is
difficult to know whether the discontinuation of one of the
ARVs in a suppressive regimen constitutes the removal of a
key regimen component that will not be adequately sup-
planted by a substituted ARV. In such patients it is necessary
to consider past drug resistance test results and past ARVs to
which drug resistance may have developed but may not have
been documented by resistance testing [50, 51].
Table 3 summarizes the design and main findings of most
of the randomized controlled trials of ART modification in
virologically suppressed patients. The trials are grouped
according to the ARV classes substituting for one another. In
most trials, virologic suppression was defined as a VL below
50–75 copies/ml for 12–24 weeks. Histories of VF or drug
resistance were exclusion criteria for many of the studies.
The primary endpoint in most trials was the proportion
of patients with VF by week 48, where VF was defined as
the development of HIV RNA levels above a particular
threshold ranging from 50 to 400 copies/ml. HIV RNA
levels were assessed at either a single time point as in the
FDA Snapshot analysis [77] or had to be confirmed with a
repeat test. To preserve the principles of intention-to-treat,
several studies distinguished primary VF from treatment
failure, which included primary VF, treatment discontinu-
ation because of intolerance or drug toxicity, and losses to
follow-up. The difference among treatment groups was
often assessed using a non-inferiority analysis in which the
lower bound of the confidence interval for the difference in
proportions of successfully treated patients was compared
using a pre-specified margin of difference usually between
10 and 20 %.
4 ART Modification Strategies
The following sections organize ART modifications in
patients with stably suppressed virus according to the
ARV class of a drug that requires discontinuation and the
ARV class of its replacement drug. Three sections
address ART modifications that involve discontinuing
NRTIs, PIs, and NNRTIs regardless of whether discon-
tinuation is required to manage toxicity, address drug–
drug interactions, or improve adherence. Additional sec-
tions address the potential roles for boosted PI
monotherapy, boosted PIs plus lamivudine, and boosted
PIs plus an integrase strand transfer inhibitor (INSTI),
several unorthodox ART modification approaches, and
the discontinuation of ENF.
4.1 Discontinuation of a Nucleoside Reverse
Transcriptase Inhibitor (NRTI)
d4T, ddI, and to a lesser extent AZT are associated with a
wide range of toxicities as a result of their off-target
inhibition of human mitochondrial gamma polymerase [19,
Table 2 Recommended, alternative and other ART regimen options
(US Department of Health and Human Services Guidelines) [1]a
Class Baseb NRTI backbonec
TDF/FTC ABC/3TC
INSTI RAL Recommended Other
EVG/c Recommended Not recommended
DTG Recommended Recommended
PI DRV/r or DRV/c Recommended Alternative
ATV/r or ATV/c Alternative Alternative
LPV/r Other Other
NNRTI EFV Alternative Other
RPV Alternative Not recommended
3TC lamivudine, ABC abacavir, ART antiretroviral therapy, ATV
atazanavir, c cobicistat, EFV efavirenz, EVG elvitegravir, FTC
emtricitabine, INSTI integrase strand transfer inhibitor, LPV lopinavir,
NNRTI non-nucleoside reverse transcriptse inhibitor, NRTI nucleos(-
t)ide reverse transcriptase inhibitor, PI protease inhibitor, r low-dose
ritonavir, RAL raltegravir, TDF tenofovir disoproxil fumarate
a Additional other regimens include DRV/r ? RAL, LPV/r ? 3TC,
and DRV/r ? 3TC
b RPV should be used as initial therapy only in patients with HIV
RNA below 100,000 c/ml and a CD4 count greater than 200 cells/m3.
Cobicistat is not recommended for use in patients with creatinine
clearance\70 ml/min
c Patients receiving ABC should be HLA-B*5701 negative. Patients
with creatinine clearance below 50 ml/min should have the TDF
dosing interval adjusted in accordance with the product label. EFV
plus 3TC/ABC and ATV/c or ATV/r plus 3TC/ABC should be used in
patients with HIV RNA below 100,000 copies/ml





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Modifying Antiretroviral Therapy 83
20] (Table 1). Although d4T and ddI are no longer rec-
ommended and although AZT is indicated solely for the
treatment of certain drug-resistant HIV strains [1, 2, 45],
one still occasionally encounters patients on these older
NRTIs.
Table 3 summarizes seven studies in which the NRTI
backbones ABC/3TC and TDF/FTC were compared as
ART modification options. Three studies enrolled patients
receiving older NRTIs randomized to receive ABC/3TC or
TDF/FTC. These studies confirmed that stably suppressed
patients can be switched from AZT or d4T to TDF or ABC
without an increased risk of VF [52, 53, 58]. Two studies
enrolled patients receiving ABC/3TC plus a ritonavir-
boosted PI [54, 55], one enrolled patients receiving ABC/
3TC/EFV [57], and one enrolled patients receiving TDF/
FTC plus a a ritonavir-boosted PI [56]. Taken as a whole,
these studies demonstrated borderline increases in VF with
ABC/3TC and small reductions in renal function and bone
density with TDF/FTC. In three studies, a change from
ABC/3TC to TDF/FTC was associated with modest
reductions in LDL cholesterol but not in the total/HDL
cholesterol ratio. In one study, there was an increased risk
of cardiac events with ABC/3TC (2.2 per 100 patient-
years) compared with TDF/FTC (0.3 per 100 patient-years;
p = 0.05) [53].
Although TDF and ABC are equally potent inhibitors of
HIV-1 replication [54, 56, 78], TDF has a more favorable
cross-resistance profile primarily because the most com-
mon NRTI-resistance mutations M184V/I cause low-level
reduction in ABC susceptibility but increased TDF sus-
ceptibility [79, 80]. Therefore, in patients with possible
pre-therapy resistance, a switch from TDF to ABC carries
an inherently higher risk of emerging drug resistance than a
switch from ABC to TDF. Additionally, before discontin-
uing TDF it is also necessary to know whether a patient is
HBsAg positive because such patients would require an
additional anti-HBV agent such as entecavir to prevent
HBV rebound, hepatitis flare, and the development of HBV
resistance to 3TC and FTC [1].
When there are relative or absolute contraindications to
both ABC and TDF, it is possible to switch virologically
suppressed patients without PI resistance to DRV/r or
LPV/r monotherapy or DRV/r, LPV/r or ATV/r in com-
bination with 3TC (Table 4). The pro and cons of this
strategy and the supporting clinical trials are described in
a Sect. 4.4. NRTI discontinuation has also been proposed
for ARV-experienced patients in whom levels of NRTI
resistance are so high that their predicted benefit does not
appear to outweigh their toxicity and cost. However,
unless the aforementioned boosted PIs are fully active,
one or more ARVs from an additional class will also be










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































84 S. E. Collins et al.
4.2 Discontinuation of a Protease Inhibitor (PI)
Ritonavir-boosted PIs are among the most common ARVs
requiring substitution because they are more likely than
NNRTIs and INSTIs to be associated with gastrointestinal
intolerance, elevated lipids, and drug–drug interactions
[21]. Although each of the most commonly used PI/r’s—
DRV/r, ATV/r, and LPV/r—can have these side effects,
they are usually more severe with LPV/r. This is due in part
to LPV’s uniform requirement for 200 mg rather than
100 mg of ritonavir for boosting.
It is not yet known whether adverse effects associated
with DRV/cobicistat (DRV/c) and ATV/cobicistat (ATV/c)
are less frequent than those associated with DRV/r and
ATV/r, but initial data suggest that these new formulations
have a similar side-effect profile [91]. Jaundice from
unconjugated hyperbilirubinemia is the most common side
effect of pharmacologically boosted ATV and it often
requires a treatment change in patients who find the con-
dition disturbing [38]. ATV/r is also associated with an
increased risk of nephrolithiasis [92]. There are three main
approaches to modifying therapy in virologically sup-
pressed patients with PI-associated toxicity including
changing therapy to a different boosted PI or unboosted
ATV (at an increased dose of 400 mg daily), changing
therapy to an INSTI, or changing therapy to an NNRTI.
4.2.1 Switching Among PIs
Table 3 summarizes six clinical trials that studied the effect
of changing PI therapy in virologically suppressed patients.
In three trials, previously treated patients receiving LPV/r
or an older PI were randomized to either continued therapy
or to a change from LPV/r to ATV/r or ATV while con-
tinuing the other ARVs in their regimen [60, 61, 64]. In one
trial, previously treated patients on ATV/r were random-
ized to either continued ATV/r or a change to ATV [56]. In
two trials, previously ART-naı¨ve patients received an
induction regimen of ATV/r plus two NRTIs and were then
randomized to continued therapy or change to unboosted
ATV [62, 63]. Previous VF on a PI-containing regimen was
an exclusion criterion in all but one trial. Because TDF
reduces ATV levels, studies of unboosted ATV did not
include patients with stable virologic suppression on a
TDF-containing regimen.
The SWAN trial compared a switch to ATV/r or ATV
with continued therapy with one of the older, generally less
well tolerated PIs. It demonstrated that a change to ATV/r
or ATV was associated with a lower risk of VF than con-
tinued therapy (7 vs. 16 %; p = 0.004) [60]. One-third of
the patients in the SWAN study were initially receiving
LPV/r and two-thirds were receiving PIs that are now
rarely used, including nelfinavir (NFV), indinavir (IND),
and saquinavir (SQV). Two of the five trials reported an
improved lipid profile associated with a switch to ATV/r or
ATV, and one reported a modest reduction in hyper-
bilirubinemia in patients switching from ATV/r to ATV
[63].
LPV/r and DRV/r have a strong track record for salvage
therapy in patients with high-level NRTI resistance [93,
94]. Two lines of evidence suggest LPV/r and DRV/r have
a higher genetic barrier to resistance than boosted ATV.
First, these boosted PIs usually require three or more drug-
resistance mutations (DRMs) in the protease before most of
their inhibitor activity is lost [95, 96]. In contrast, a single
protease DRM is often sufficient for the loss of ATV/r
activity. Second, LPV/r and DRV/r have significantly
higher clinical phenotypic cut-offs compared with ATV/r
[97]. Despite the favorable outcome of a change to ATV/r
or ATV in these trials, they do not provide evidence sup-
porting the switch from LPV/r or DRV/r to ATV/r in stably
suppressed patients with a history of previous VF [98, 99].
However, changes from ATV or ATV/r to either LPV/r or
DRV/r would be expected to maintain virologic suppres-
sion, regardless of a patient’s past treatment history.
4.2.2 Switching from PIs to Integrase Strand Transfer
Inhibitors (INSTIs)
There are five randomized clinical trials in which stably
suppressed patients have switched therapy from a PI/r to an
INSTI (Table 3). The STRATEGY-PI, STRIIVING, and
GS Study 109 trials enrolled patients without a history of
VF or resistance to TDF or FTC [67, 75, 76]. The
SWITCHMRK and SPIRAL studies included patients with
a history of VF [65, 66].
In the STRATEGY-PI study, there were significantly
more treatment failures in patients continuing an LPV/r,
ATV/r, or DRV/r-containing regimen than those switching
to TDF/FTC/elvitegravir/cobicistat (EVG/c) (13 vs. 6 %;
p = 0.025), the difference driven by discontinuations for
non-virologic reasons. Preliminary results from the GS
Study 109, which randomized 1,436 suppressed partici-
pants on TDF/FTC plus either EVG/c (32 %), EFV (26 %),
ATV/r, or ATV/c (42 %) to a FDC of TAF/FTC/EVG/c or
continued therapy was superior at 48 weeks with 97 versus
93 % suppressed (p\ 0.001) [76]. Small improvements
were seen in short-term measures of bone density and renal
function in participants in the switch arm.
The STRIIVING study also switched virologically
suppressed patients without a history of VF who were
HLA*B-5701 negative from a variety of first-line regimens
to the FDC of ABC/3TC/DTG and compared them to those
who continued their current treatment. This switch was
non-inferior to continued therapy at 24 weeks with 85
versus 88 % maintaining virologic suppression [75].



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































86 S. E. Collins et al.
Analysis of adverse events noted that ten participants
randomized to ABC/3TC/DTG (4 % of the total) but 0
participants who did not change therapy stopped ARVs due
to various forms of intolerance.
In the SWITCHMRK trials (SWITCHMRK 1 and
SWITCHMRK 2), 702 patients stably suppressed on LPV/r
plus two NRTIs for 12 weeks were randomized to either
continued therapy or a switch to RAL ? 2 NRTIs [65].
Approximately 60 % of patients in the trials had received
one or more previous ART regimens and approximately
30 % of patients had a history of VF on an earlier regimen.
Despite having screening plasma HIV-1 RNA levels below
50 copies/ml, 5 % had detectable viremia (median RNA
level: 101 copies/ml; IQR: 63–193) immediately prior to
starting study drugs.
Within 12 weeks, patients who had switched to RAL
experienced reductions in their non-HDL cholesterol and
triglyceride levels of 15 and 42 %, respectively. However,
the trial was terminated prematurely because, by 24 weeks,
VF was significantly more likely in patients who had
switched to RAL than in those who had continued their
previous regimen (15.6 vs. 9.4 %). Among those patients
with VF who underwent genotypic resistance testing, most
had developed RAL resistance. Of the 32 RAL recipients
with VF, 27 (84 %) reported that the LPV/r regimen at
study entry was not their first ART regimen, and 18 of
these 27 had a history of previous VF. Of the 17 RAL
recipients with a baseline RNA level above the 50 copies/
ml threshold of detection, seven developed VF.
The SPIRAL trial enrolled 273 patients most of whom
were stably suppressed for 24 weeks on LPV/r (44 %),
ATV/r (35 %), or FPV/r (12 %), then randomized them to
either continue therapy or to switch to RAL [66]. Nearly
90 % of these patients had received one or more previous
ART regimens and nearly 40 % had a history of VF. At
48 weeks, treatment failure had occurred in 11 % of
patients receiving RAL and in 13 % of those remaining on
PI/r’s. Possible reasons for the discordant results between
SWITCHMRK and SPIRAL may be the longer period of
virologic suppression prior to randomization in SPIRAL or
genotypic resistance to the NRTI backbone, which was
detected in half of SWITCHMRK participants who failed
RAL but not in SPIRAL.
The significant increase in VF in patients switching to
RAL in the SWITCHMRK studies underscores the
importance of an uncompromised NRTI backbone in
patients receiving RAL. Although RAL and EVG/c may be
as potent antiviral inhibitors as the currently used PI/r’s,
they have lower genetic barriers to resistance. Just one or
two drug resistance mutations may be sufficient to cause
high-level RAL and EVG resistance [100], whereas four or
more drug resistance mutations are usually required for
high-level LPV/r or DRV/r resistance [95, 96]. Three or
more drug-resistance mutations in the integrase gene
region are usually required for DTG resistance [101–103],
and DTG has been shown to be more effective than RAL at
treating ARV-experienced patients with VF [104]. An
ongoing study of ABC/3TC/DTG for second-line therapy
in patients with NRTI-resistant viruses will provide insight
into the ability of DTG-containing regimens to maintain
virologic suppression in PI/r-treated patients with under-
lying NRTI resistance [105].
4.2.3 Switching from PIs to Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs)
There have been two studies in which stably suppressed
patients without a history of VF switched therapy from a
PI/r to an NNRTI. The first of these studies, AI266073,
enrolled patients receiving a wide range of PI- and NNRTI-
containing regimens and randomized them to either con-
tinued therapy or a switch to TDF/FTC/EFV [69]. Over a
period of 48 weeks, 89 % of patients receiving TDF/FTC/
EFV and 88 % whose therapy was unchanged maintained
virologic suppression.
The second study, SPIRIT, enrolled patients receiving
mainly ATV/r, LPV/r, and DRV/r who had no history of
VF or prior ART and no evidence for NRTI or RPV
resistance. These patients were randomized to switch to
TDF/FTC/RPV or to continue their current therapy [49].
After 24 weeks, there was no difference in VF between the
two groups (6 % of those who had switched to TDF/FTC/
RPV and 10 % of those who did not change therapy
experienced VF; p = 0.15). Of note, none of the 18
patients with a pre-ART genotype containing K103N, the
commonly transmitted nevirapine (NVP) and EFV-resis-
tance mutation, developed VF on TDF/FTC/RPV. Plasma
HIV-1 RNA levels prior to the start of their initial PI/r
containing regimen did not predict VF, suggesting that
once virus loads are stably suppressed the risk of VF may
not be greater in patients with pre-therapy RNA levels that
exceed 5.0 log10 copies/ml.
One of the earliest ART modification studies substituted
EFV, NVP, or ABC for a PI in patients with plasma HIV-1
RNA levels below 200 copies/ml for 24 weeks. Approxi-
mately 90 % of these patients were receiving IDV or NFV,
and approximately 50 % had a history of mono or dual
NRTI therapy prior to attaining virologic suppression [68].
At 12 months, the Kaplan–Meier estimates of VF or dis-
ease progression were 6 % in the EFV group, 10 % in the
NFV group, and 13 % in the ABC group. A history of
suboptimal therapy prior to attaining virologic suppression
was a strong risk factor for VF with 23 of 29 patients with
VF having a history of mono- or dual NRTI therapy.
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4.3 Discontinuation of an NNRTI
NVP is no longer recommended as a preferred medication
by the WHO, DHHS, or EACS for any specific indication
and is now used infrequently in middle- and upper-income
countries [1, 2, 45]. NVP is associated with severe hyper-
sensitivity including rash and hepatitis in about 2 % of
patients and less severe abnormalities in up to 10 % [19,
41, 46]. EFV is a key component of most WHO-recom-
mended ART regimens. It was recently removed from the
list of DHHS-Recommended ART regimens, but the FDC
of TDF/FTC/EFV remains in wide use as a DHHS-Alter-
native regimen. Central nervous system symptoms are the
main side effects of EFV [33–35]. The dose-dependency of
these symptoms and the frequency with which they persist
to cause non-adherence or serious morbidity is now being
studied as newer FDCs have become available for com-
parison [34–36].
The newer NNRTIs etravirine (ETR) and RPV have
fewer safety and tolerability concerns than NVP and EFV.
Although ETR and RPV have similar cross-resistance
profiles, ETR is considerably more potent and has a higher
genetic barrier to resistance because the recommended
400-mg daily dosage of ETR is 16-fold higher than the
recommended 25-mg daily dosage of RPV. The lower daily
dosage of RPV is due to the fact that healthy, non-infected
human volunteers experienced QT prolongations at doses
of 75 mg or higher [106]. However, the high potency and
lack of co-formulation of ETR mean it is primarily used as
a salvage therapy option.
4.3.1 Switching Among NNRTIs
There have been two randomized, blinded studies in
which a small number of patients receiving an EFV-
containing regimen were randomized to either switch to
ETR 400 mg once daily or to continue EFV, and one non-
randomized study in which a small number of patients
receiving TDF/FTC/EFV were switched to TDF/FTC/
RPV (Table 3). These studies suggest that despite the
inductive effects of EFV on CYP450 3A4, such a switch
can occur without jeopardizing virologic suppression
because EFV levels remain therapeutic while RPV (and
presumably also ETR) levels increase [72, 107]. These
studies also suggest that those patients with persistent
central nervous system symptoms on EFV will experience
a reduction of these symptoms with ETR (and presumably
also RPV) [70]. Because TDF/FTC/RPV has been asso-
ciated with a greater risk of emergent drug resistance
compared with TDF/FTC/EFV [108–110], switching from
TDF/FTC/EFV to TDF/FTC/RPV should only be done in
patients without a history of VF or evidence of resistance
to TDF, FTC, or RPV.
4.3.2 Switching from NNRTIs to an INSTI
A randomized, double-blind, crossover study of a small
number of patients switching from EFV to RAL demon-
strated a significant reduction in anxiety while patients
were on RAL [73]. The much larger STRATEGY-NNRTI
demonstrated the non-inferiority of a switch from an
NNRTI plus two NRTIs to the FDC of TDF/FTC/EVG/c
and also noted a reduction in sleep disturbances in patients
switching to EVG/c [74, 111]. The aforementioned GS
Study 109 and STRIVIING studies both enrolled substan-
tial proportions of participants on NNRTI-based therapy
(31 and 26 %) and switched them to INSTI-based therapy,
supporting the efficacy of this modification strategy [75,
76].
4.3.3 Switching from NNRTIs to PIs
Pharmacologically-boosted PIs have higher genetic barriers
to resistance than NNRTIs and switches from NNRTIs to
boosted PIs are commonly made in patients failing
NNRTI-based therapy. Changing the NNRTI component of
a virologically suppressive regimen to pharmacologically
boosted DRV or ATV—the most well tolerated of the
DHHS Acceptable first-line PIs—is likely to be highly
effective in most virologically suppressed patients. This
type of switch, however, has not been studied in virologi-
cally suppressed patients because boosted PIs have been
highly effective substitutes for an NNRTI even in patients
with VF [37, 93, 112].
4.4 Boosted PI Mono or Dual Therapy
A large number of randomized clinical trials suggest that
LPV/r and DRV/r monotherapy are effective options for
stably suppressed patients without a history of PI resistance
(Table 4) (reviewed in Arribas et al. [113, 114]). Although
LPV/r and DRV/r monotherapy are associated with an
increased risk of virologic rebound compared with triple
ART, this viral rebound is rarely associated with emergent
drug resistance. The re-administration of NRTIs in these
patients nearly always leads to re-suppression of virus
levels to below 50 copies/ml [81, 82, 84–87, 115]. The risk
of VF in patients receiving PI/r monotherapy is strongly
associated with a patient’s nadir CD4 count and may be
confined to patients with nadir CD4 counts below 200
cells/mm3 [87, 116].
Several small studies suggest that ATV/r monotherapy
is associated with a higher risk of VF than LPV/r and
DRV/r monotherapy [88, 89, 117–119]. One large obser-
vational study suggests that DRV/r is also more effective
than LPV/r [120]. Although patients receiving PI/r
monotherapy have an elevated risk of detectable CSF virus
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when compared with those receiving triple therapy, they do
not appear to have an increased risk of central nervous
system symptoms [116, 121–124].
Several recent and ongoing trials have shown that
LPV/r, ATV/r, and DRV/r in combination with 3TC are
not associated with an increased risk of virologic
rebound compared with PI/r’s plus two NRTIs provided
there is no baseline 3TC resistance [83, 90, 125]. Sup-
porting this concept the GARDEL trial showed that a
regimen of LPV/r plus 3TC is as effective as LPV/r plus
two 2 NRTIs as initial therapy in ARV-naı¨ve patients
[126].
4.5 Boosted PIs Plus INSTIs
There have been several clinical trials in which LPV/r,
DRV/r, and ATV/r have been used in combination with
RAL for first- and second-line therapy or for mainte-
nance therapy in virologically suppressed patients [22,
92–94, 127–129]. These trials have shown the following:
(1) DRV/r plus RAL was comparable to DRV/r plus
TDF/FTC for first-line therapy except in patients with
high VL or low CD4 counts where DRV/r plus RAL was
less effective in subgroup analyses [127]; (2) LPV/r plus
RAL was virologically comparable to but no better than
LPV/r plus two NRTIs in patients with previous VF on a
first-line NRTI plus NNRTI-containing regimen [93, 94];
(3) LPV/r plus RAL and DRV/r plus RAL were com-
parable to LPV/r and DRV/r plus two NRTIs in viro-
logically suppressed patients [22, 92]; and (4) ATV/r
plus RAL was associated with a higher risk of virologic
rebound (7/72; 10 %) compared with ATV/r plus TDF/
FTC (1/37; 3 %) in patients with stable virologic sup-
pression [128].
Regardless of the clinical scenario and boosted PI,
many patients with VF developed RAL-resistance muta-
tions that would limit future treatment options. Even
under the most favorable circumstances—the use of DRV/r
plus RAL for first-line therapy in closely monitored
patients [127]—a drug-resistance sub-study showed that
4 % of 805 patients developed RAL resistance by week 80
[130]. A likely explanation for this finding is that the
prevention of RAL resistance may require a consistently
high level of boosted PI adherence that is often not
achieved outside of a clinical trial. Therefore switching
stably suppressed patients to a boosted PI plus INSTI-
containing regimen should be restricted to the use of
boosted DRV—because of its combination of tolerability
and high genetic barrier to resistance—plus RAL or DTG
and should be done primarily for the management of NRTI
toxicity in highly adherent patients without a history of PI
resistance.
4.6 Discontinuation of Enfuvirtide (ENF)
The demonstration that virologically suppressed patients
receiving ENF could switch to RAL without risking viro-
logic rebound [131–134] paved the way for many of the
ART modification studies that followed. As several addi-
tional, highly potent and novel ARVs were approved (in-
cluding DRV, ETR, and RAL), the number of patients
receiving ENF has decreased dramatically. The few
patients currently receiving ENF are likely to have failed
many ARV regimens and to have extensive resistance to
the more commonly used drug classes. ENF discontinua-
tion in these patients requires expert consultation to choose
an individually tailored replacement ART regimen with
sufficient antiviral potency and a genetic barrier high
enough to replace ENF.
4.7 Miscellaneous Other Regimens
4.7.1 Maraviroc-Containing Regimens
In patients for whom MVC is being considered it is nec-
essary to exclude the presence of CXCR4 tropic variants,
which would render MVC inactive. In virologically sup-
pressed patients, however, it is not possible to test plasma
virus for CXCR4 tropism. Therefore several commercial
laboratories have developed proviral DNA tropism assays.
The ‘‘Appendix’’ summarizes the rationale for proviral
drug resistance and tropism assays in virologically sup-
pressed patients [50, 51, 135–140].
One small trial assessed the possible role of maraviroc
(MVC) in virologically suppressed patients on a three-drug
PI/r- or NNRTI-containing regimens by randomizing 30
such patients to either switch to MVC plus two NRTIs or to
continue their therapy [141]. Additional inclusion criteria
included a negative proviral DNA genotypic test for
CXCR4-tropic viruses and no history of NRTI resistance.
Although only one of the 15 patients randomized to MVC
developed VF—a patient subsequently found to have
CXCR4-tropic virus missed by the screening tropism
assay—this strategy cannot be recommended until further
studies are performed [1].
4.7.2 Triple NRTIs
There have been two meta-analyses of randomized con-
trolled trials published between 2001 and 2013 in which
stably suppressed patients on two NRTIs plus an NNRTI or
a PI were placed on a three-drug ABC-containing regi-
men—usually AZT/3TC/ABC—to simplify therapy and
reduce lipid levels [142, 143]. These meta-analyses con-
cluded that AZT/3TC/ABC appeared to be as effective as
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continued two-class therapy but cautioned that the ARVs
used in those studies were often inferior to those currently
used. However, as a result of the established inferiority of
AZT/3TC/ABC for first-line therapy [144], this regimen is
generally not considered a suitable option for maintenance
therapy in virologically suppressed patients.
4.7.3 Non-NRTI-, Non-PI-Containing Regimens
There have been several pilot studies of combinations of
ARVs including RAL plus MVC [145], RAL plus ETR
[146], and the long-acting investigational INSTI cabote-
gravir in combination with RPV [147]. The RAL plus
MVC trial was discontinued prematurely because it was
associated with a high rate of virologic failure. VF occur-
red in only one of 25 patients receiving RAL plus ETR at
48 weeks, two others discontinued because of intolerance.
4.7.4 Long-Acting Parenteral Therapy
Long-acting injectable ARVs may soon provide novel
treatment strategies in HIV-infected patients who cannot
take oral pills for medical reasons (surgery or transplant),
for whom adherence to daily oral medications is poor or for
prevention of HIV in uninfected patients. For example, the
phase IIb LATTE study used an oral induction phase with
cabotegravir (an INSTI) plus two NRTIs; participants who
were suppressed after 24 weeks were switched to a main-
tenance regimen of dual therapy cabotegravir plus RPV. At
week 96, virologic suppression for the experimental regi-
men was similar to EFV plus two NRTIs [147]. Both
cabotegravir and RPV have the potential to be administered
as long-acting injectable formulations. A study evaluating a
similar switch strategy from standard ART to dual therapy
oral DTG plus RPV is also underway [148].
5 Conclusions and Future Directions
In patients who have never experienced VF while receiving
ART and have no evidence of drug resistance, switching to
any of the acceptable DHHS first-line regimens is expected
to maintain virologic suppression. An increasing number of
clinical trials of once daily FDC combinations offer con-
venience for patients and have now been shown to be both
highly effective for maintaining virologic suppression in
this population. Even in these patients with little risk of
virologic failure, changes can expose them to medication
intolerance or adverse effects, so the indications for
switching therapy should be carefully considered.
In virologically suppressed patients with a history of VF
or drug resistance, it is more challenging to change therapy
while still maintaining virologic suppression. In these
patients, it is necessary to consider all past ARV regimens,
episodes of VF, and past genotypic resistance tests. Addi-
tionally, it is usually necessary to select a regimen with a
high genetic barrier to resistance and occasionally neces-
sary to select a regimen containing ARVs from more than
two drug classes.
A growing number of studies have included switches to
INSTI-based regimens. The pivotal SWITCHMRK trial
showed that the substitution of RAL for LPV/r carries a
risk of VF and emergent INSTI resistance in patients har-
boring NRTI-resistant viruses. As a result of this finding,
clinical trials of switches to newer INSTIs (EVG/c and
DTG) have been performed almost exclusively in patients
without a history of past VF or evidence of drug resistance
mutations. In contrast, DTG – which has a higher genetic
barrier to resistance than RAL or EVG/c and is currently
being studied as an option for second-line therapy in
patients who have failed a first-line NNRTI-based regimen
[105] – may eventually prove to be a switch option in
stably suppressed patients with prior VF. Results of a study
that switched patients with prior VF who are now sup-
pressed on a complex regimen to the FDC TAF/FTC/EVG/c
plus DRV are expected in the near future [149].
Increasing data show that LPV/r or DRV/r, either alone
or in combination with 3TC, are effective maintenance
regimens in patients without previous PI or 3TC resistance.
These regimens are likely to be useful in patients with
NRTI toxicity. However, in patients without such toxicity
they may be complicated to administer because they
require closer follow-up for VF. LPV/r or boosted DRV
plus an INSTI have also been effective maintenance regi-
mens, and are useful options for patients with NRTI toxi-
city. Patients receiving such regimens must be particularly
adherent to the boosted PI component of the regimen
because non-adherence poses a high risk of emergent
INSTI resistance and loss of future options.
Genotypic resistance and co-receptor tropism testing
from peripheral blood mononuclear cells are commercially
available but not frequently used. They assess the proviral
DNA that is integrated into resting memory CD4? T cells
forming an ‘‘archive’’ of resistance mutants that can be
sequenced when no virus is detected in the blood. These
tests are likely to be reliable when they detect resistance
mutations or CXCR4 tropism but the validity of negative
assays requires further study.
6 Case Vignettes
6.1 Case 1
A 46-year-old woman with a 15-year history of ART ini-
tially with SQV/r/D4T/3TC then with EFV/TDF/FTC
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presented with progressive renal dysfunction and a partial
Fanconi syndrome. She had no known history of VF or
drug resistance. Her CD4 count was 1,056 cells/mm3 and
her viral load was consistently below 50 copies/ml. She
also has a history of migraine headaches often requiring
intravenous dihydroergotamine infusions.
Her progressive renal dysfunction and tubular dysfunc-
tion made it urgent to discontinue TDF. An HLA*B5701
test, which was performed to ensure that ABC was a viable
option, was negative. Given her preference for a once-daily
single-table regimen, she was changed to ABC/3TC/DTG.
Her renal function has since improved and she has
remained virologically suppressed. Simply substituting
ABC for TDF was considered to be an inferior option
because of the possibility that during her long past period
of treatment she may have developed some degree of latent
NRTI or NNRTI resistance that might reactivate due to the
lower activity of ABC compared with TDF in the face of
resistance. A boosted PI regimen was not used because of
the established drug–drug interaction between boosted PIs
and dihydroergotamine.
6.2 Case 2
A 42-year-old man with a history of hypertension had been
treated initially with TDF/3TC/EFV and then TDF/FTC/
EFV for a total of 9 years. He had no known history of VF
and had a nadir CD4 count of 262 cells/mm3. During the
past year, he has developed progressively increasing anx-
iety and depression requiring visits to a psychiatrist who is
inquiring about the possibility of discontinuing EFV before
starting an antidepressant.
Although it is unusual for EFV-associated neuropsy-
chiatric symptoms to develop so late into therapy, it is
possible that EFV could be exacerbating these symptoms
even if it is not their primary cause. Considering the
absence of any history of VF or drug resistance, the patient
has many treatment options including each of the three
DHHS-recommended single tablet regimens: TDF/FTC/
RPV, TDF/FTC/EVG/c, and ABC/3TC/DTG. The newly
available TAF/FTC/EVG/c FDC is also supported by evi-
dence but not yet incorporated into treatment recommen-
dations. In this patient, we chose to use TDF/FTC/RPV.
The patient’s depression and anxiety improved dramati-
cally within several weeks and his virus load remained
undetectable.
6.3 Case 3
A 72-year-old man with a more than 20-year history of
ART has been stably suppressed on TDF/FTC/ATV/r for
8 years. He began therapy in the early 1990s with a series
of mono- and dual-NRTI regimens. He has a history of
EFV and LPV/r intolerance. His nadir CD4 count was 70
cells/mm3 and his last genotypic resistance test prior to
starting TDF/FTC/ATV/r contained multiple thymidine
analog resistance mutations, M184V, and several NNRTI-
resistance mutations. A recently ordered HLA-B*5701 test
was negative. Although he has no history of coronary
artery disease, he has inquired about the possibility of
switching ATV/r to an INSTI to reduce that risk. Inter-
estingly, a genotypic resistance test of proviral DNA
detected the presence of three TAMs, M184V, and two
NNRTI-resistance mutations that closely matched the pat-
tern of resistance observed on his last test prior to starting
his current regimen.
At the time the patient first made this inquiry DTG had
not yet been approved and it was decided that a switch to
RAL or to TDF/FTC/EVG/c would entail an increased risk
of VF because of the partially compromised NRTI back-
bone. Since then DTG has been approved and, due to its
higher genetic barrier to resistance, is likely to be associ-
ated with a lower risk of VF and emergent INSTI resistance
than RAL or EVG/c. However, considering the relatively
weak association of ATV/r with an atherogenic lipid profile
and the fact that clinical trials of DTG in this scenario have
not yet been completed, it was decided to continue the
patient’s current therapy.
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Appendix: Proviral DNA Testing for HIV-1 Drug
Resistance and Co-Receptor Tropism in Patients
with Virological Suppression
During its replication cycle, proviral HIV-1 DNA inte-
grates into host chromosomal DNA and is then usually
expressed leading to productive infection and cell killing.
In resting memory CD4? T cells, however, integrated
proviral DNA may persist for many years forming a
stable reservoir of latently infected cells [135]. As a result,
proviral DNA levels in peripheral blood mononuclear cells
(PBMCs) remain detectable even in patients receiving
ART who have undetectable plasma HIV-1 RNA levels
[136, 7].
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There is a strong but imperfect correlation between the
drug-resistance mutations (DRMs) in PBMC proviral DNA
and plasma HIV-1 RNA from the same blood samples [50,
137]. Indeed, in patients with suppressed plasma HIV-1
RNA levels, the DRMs present in PBMCs are consistent
with a patient’s past ART history and previous genotypic
tests [51, 138, 139]. However, PBMC sequencing does not
necessarily detect all of the DRMs that were previously
present in samples from patients who had past genotypic
resistance tests [51, 139, 150]. Therefore, PBMC genotypic
resistance should be used in conjunction with past geno-
typic test results and should be interpreted in light of drug
resistance likely to have emerged during past episodes of
virological failure.
Most studies suggest that little HIV-1 evolution occurs
during ART-mediated virological suppression—particu-
larly with most current regimens [15]. Therefore, if co-
receptor tropism was determined shortly before virological
suppression, it is unlikely to have changed during therapy
[140]. However, if tropism was not determined previously
and if a switch to maraviroc is being considered, genotypic
or phenotypic PBMC tropism tests are considered reason-
able but have not been validated for predicting maraviroc
activity [1].
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